Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter.
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.24. On average, analysts expect Corbus Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.
Corbus Pharmaceuticals Price Performance
Shares of CRBP stock opened at $7.50 on Tuesday. The business's fifty day moving average price is $6.42 and its 200 day moving average price is $11.46. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $61.90. The firm has a market capitalization of $91.74 million, a PE ratio of -1.60 and a beta of 3.12.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on CRBP shares. Wedbush reaffirmed an "outperform" rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Jefferies Financial Group dropped their price objective on Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. William Blair started coverage on Corbus Pharmaceuticals in a report on Friday, February 28th. They set an "outperform" rating on the stock. StockNews.com raised Corbus Pharmaceuticals to a "sell" rating in a report on Thursday, March 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 target price (down from $75.00) on shares of Corbus Pharmaceuticals in a research report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $59.13.
Read Our Latest Stock Report on Corbus Pharmaceuticals
About Corbus Pharmaceuticals
(
Get Free Report)
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Corbus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corbus Pharmaceuticals wasn't on the list.
While Corbus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
